and most important of all.....NO COMPETITION
no matter since the company will be sold within the 5 year note period..
I've been waiting for the secondary and good it's out of the way and they get rid of a 12% loan....all good
that when it was approved he thought it was good and going higher, but
"people" told him that it wouldn't be taken up by doctors.....so hence he's back with the shorts. Who told you Jim? How did you verify that they are correct and it wouldn't be taken up my doctors? You thought it was good Jim, but some "people" dissuaded you from your own original thoughts.....how can that be almighty Jim....you are the supreme being...................back in the shorts pocket he is..........actually, he never left, but he was beaten when drug approved and he knew it and submitted..................until some "people" set him straight...
no risk at all if your short..if the stock closes over the stock price the premium you sold it for is yours. If the stock closes under the strike price they will put you to buy the stock which you will use to offset your short position.
you need an out of the money call, preferably as cheap as you can get it...problem is there is a lot of premiums already built into the call. You can also sell some puts at around the 10 or 11 price and if they go under the strike price they will put you the stock (must buy) and this will offset some of your losses..
last I checked Tysabri had way over 100 deaths........so take your fear tactics somewhere else.
interesting, when a patient gets PML they usually die within 2-4 maybe 6 months. If this patient had PML for 4 years then it's quite a miracle that the patient lasted as long...
11:30 a.m. ET: Ebola has Ivy League potential. The suspected Ebola case at Yale-New Haven Hospital is a Yale University student who returned home on Oct. 11 from conducting research in Liberia, New Haven Mayor Toni Harp’s office and hospital officials told NECN Thursday morning. The patient voluntarily isolated himself since he returned to the United States this weekend.
NEW YORK--(BUSINESS WIRE)--
Synergy Pharmaceuticals Inc. (SGYP) today announced that it will present additional positive data from a phase 2b study assessing plecanatide’s efficacy and safety in patients with irritable bowel syndrome with constipation (IBS-C). The data will be presented during a plenary session at the American College of Gastroenterology’s 2014 Annual Scientific Meeting in Philadelphia, Pennsylvania on October 20, 2014. Analysis of these data indicated that the study met its primary endpoint and important secondary endpoints, including the Overall Responder endpoint for IBS-C.
The oral presentation titled, “Plecanatide, a Novel Uroguanylin Analog: a 12-Week, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate Efficacy and Safety in Patients with Irritable Bowel Syndrome with Constipation (IBS-C)” (Paper # 14) will be presented by Philip B. Miner Jr., M.D., President and Medical Director of the Oklahoma Foundation for Digestive Research, during Plenary Session 1: Functional Bowel Disorders/Pediatrics, from 2:15pm – 3:00pm on Monday, October 20, 2014.
Achillion to Present Updated Clinical HCV Data on ACH-3102 and Preclinical Profile of ACH-3422 at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting
Achillion Pharmaceuticals, Inc.
7 minutes ago
- Late breaker poster presentation will feature updated SVR results from the Phase 2 trial of ACH-3102, NS5A inhibitor, plus sofosbuvir for the eight-week treatment of genotype 1 HCV -
- Three preclinical posters on ACH-3422, uridine-analog nucleotide prodrug, to be presented --
NEW HAVEN, Conn., Oct. 8, 2014 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (ACHN) today announced four abstracts have been accepted for presentation at The Liver Meeting(R) 2014, the 65th Annual Meeting of The American Association for the Study of Liver Diseases (AASLD), in Boston, November 7 -- 11.
A late breaker poster presentation will be made providing updated results, including SVR12, from an ongoing Phase 2 proxy study evaluating ACH-3102, Achillion's second-generation NS5A inhibitor, in combination with sofosbuvir, without ribavirin, for eight weeks of treatment in patients with treatment-naive genotype 1 chronic hepatitis C virus (HCV) infection. This trial is currently dosing patients in a follow-on six-week treatment cohort.
Furthermore, three additional posters will be presented detailing the preclinical profile of ACH-3422, a uridine-analog nucleotide that continues to advance through its Phase 1 clinical development program.